Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma

Purpose: The microRNA-34b/c (miR-34b/c) is considered a tumor suppressor in different tumor types and a transcriptional target of TP53. The main objectives of this study were to investigate the clinical implications of miR-34b/c methylation in patients with early-stage lung adenocarcinoma and to determine the functional role of miR-34b/c re-expression in lung adenocarcinoma cell lines. Experimental Design: Aberrant methylation and expression of miR-34b/c were assessed in 15 lung adenocarcinoma cell lines and a cohort of 140 early-stage lung adenocarcinoma. Lung adenocarcinoma cell lines were transfected with miR-34b/c and the effects upon cell proliferation, migration, invasion, and apoptosis were investigated. Results: Aberrant methylation of miR-34b/c was detected in 6 (40%) of 15 lung adenocarcinoma cell lines and 64 of 140 (46%) primary lung adenocarcinoma. Expression of miR-34b/c was significantly reduced in all methylated cell lines and primary tumors, especially with TP53 mutations. Patients with increased miR-34b/c methylation had significantly shorter disease-free and overall survival as compared to patients with unmethylated or low level of miR-34b/c methylation. Ectopic expression of miR-34b/c in lung adenocarcinoma cell lines decreased cell proliferation, migration, and invasion. Conclusions: Epigenetic inactivation of miR-34b/c by DNA methylation has independent prognostic value in patients with early-stage lung adenocarcinoma. Reexpression of miR-34b/c leads to a less aggressive phenotype in lung adenocarcinoma cell lines. Clin Cancer Res; 19(24); 6842–52. ©2013 AACR.

[1]  C. Plass,et al.  Genome-wide epigenetic regulation of miRNAs in cancer. , 2013, Cancer research.

[2]  田中 則光.  Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer , 2013 .

[3]  Joana A. Vidigal,et al.  Intact p53-Dependent Responses in miR-34–Deficient Mice , 2012, PLoS genetics.

[4]  Jian Ye,et al.  Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction , 2012, BMC Bioinformatics.

[5]  J. Soh,et al.  Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. , 2012, Lung cancer.

[6]  Christoph C Zielinski,et al.  Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non–Small Cell Lung Cancers , 2012, Clinical Cancer Research.

[7]  J. Balko,et al.  A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT , 2011, British Journal of Cancer.

[8]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[9]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[10]  F. Slack,et al.  MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.

[11]  M. Esteller.  Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[12]  H. Drexler,et al.  Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms , 2011, Journal of Translational Medicine.

[13]  J. Soh,et al.  Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma , 2011, Clinical Cancer Research.

[14]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[15]  Zhaoli Chen,et al.  DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer , 2011, Cancer biology & therapy.

[16]  B. Verdoodt,et al.  Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas , 2011, Virchows Archiv.

[17]  M. Toyota,et al.  Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. , 2010, Carcinogenesis.

[18]  Jane J. Sohn,et al.  MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. , 2010, Cancer research.

[19]  K. Kelnar,et al.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.

[20]  L. Stewart,et al.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data , 2010, The Lancet.

[21]  H. Hermeking,et al.  Frequent Downregulation of miR-34 Family in Human Ovarian Cancers , 2010, Clinical Cancer Research.

[22]  Yingdong Zhao,et al.  MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer , 2010, Clinical Cancer Research.

[23]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[24]  Min Zhang,et al.  MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells , 2009, PloS one.

[25]  A. Burny,et al.  Evolution of microRNA expression during human bronchial squamous carcinogenesis , 2008, European Respiratory Journal.

[26]  Avner Friedman,et al.  MicroRNA regulation of a cancer network: Consequences of the feedback loops involving miR-17-92, E2F, and Myc , 2008, Proceedings of the National Academy of Sciences.

[27]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[28]  S. Ropero,et al.  A microRNA DNA methylation signature for human cancer metastasis , 2008, Proceedings of the National Academy of Sciences.

[29]  Susanna M Cramb,et al.  The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[31]  Lesley Seymour,et al.  Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Toyota,et al.  Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. , 2008, Cancer research.

[33]  Artemis G. Hatzigeorgiou,et al.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[34]  Anton J. Enright,et al.  Genomic analysis of human microRNA transcripts , 2007, Proceedings of the National Academy of Sciences.

[35]  Wei Wang,et al.  MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. , 2007, Cancer research.

[36]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[37]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[38]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[39]  S. Hammond.  MicroRNAs as tumor suppressors , 2007, Nature Genetics.

[40]  T. Golub,et al.  Impaired microRNA processing enhances cellular transformation and tumorigenesis , 2007, Nature Genetics.

[41]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  Clare Stirzaker,et al.  Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band , 2006, Nature Genetics.

[43]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[44]  Z. Weng,et al.  A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome , 2006, Cell.

[45]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[46]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[47]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[48]  M Paesmans,et al.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[49]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[50]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[51]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.